The company is setting up for a showdown with the FDA over its approved gene therapy, Elevidys.
Sarepta stock took another dive Monday after the biotech company refused the Food and Drug Administration’s request to voluntarily stop all shipments of its gene therapy, Elevidys.
The FDA’s request…
📰 Article Source Information
Publisher: Investor’s Business Daily
Published: 7/21/2025 at 8:08:00 PM
Category: Business
Verification: Content sourced from authentic local and international news organizations
Original Article: https://www.investors.com/news/technology/sarepta-stock-elevidys-gene-therapy-fda-request/
This article has been republished with proper attribution to maintain journalistic integrity and provide readers with verified news content.
